Tisch MS News

Peggy Bettin (Tisch MS) presented the following article in Journal Club.

Article title: Intrathecally Synthesized IgG in Multiple Sclerosis Cerebrospinal Fluid Recognizes Identical Epitopes Over Time

Reference: X. Yu, M. Brugoon, M. Green, O. Barmina, K. Dennison, Pointon, M. Davis, and D. Gilden. J. Neuroimmunol. (2011), doi:10.1016/j.jneuroim/2011.10.009

Saud Sadiq, MD (Tisch MS, IMSMP) presented the following article in Journal Club.

Article Title: Potassium Channel KIR4.1 as an Immune Target in Multiple Sclerosis

Reference: R. Srivastava, M. Aslam, S.R. Kalluri, L. Schirmer, D. Buck, B. Tackenberg, V. Rothhammer, A. Chan, R. Gold, A. Berthele, J.L. Bennett, T. Korn, and B. Hemmer. (2012) The New England Journal of Medicine. 367 (2): 115-123.

Daniel Koffler (Tisch MS) presented the following article in Journal Club.

Article Title: Decreased Hydrocortisone Sensitivity of T Cell Function in Multiple Sclerosis Associated Major Depression

Reference: A. Fischer, C. Otte, T. Krieger, R. Nichols, S. Krüger, K. Ziegler, K. Schulz, C.Heesen, and S. Gold. (2012) Psychoneuroendocrinology. 37: 1712-1718.

The Food and Drug Administration (FDA) made an unannounced site visit to Tisch MS during the week of August 27 in connection with the proposed Tisch MS clinical trial of Mesenchymal Stem Cell-Derived Neural Progenitors (MSC-NPs). As noted in this space in August, the FDA had previously initiated an audit of the International Cellular Medicine Society (ICMS), the Institutional Review Board (IRB) which had granted approval to the MSCRNY study last November.

Deirdre Dulak (Tisch MS) presented the following article in Journal Club.

Article Title: Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis

Reference: G. Comi, D. Jeffery, L. Kappos, X. Montalban, A. Boyko, M.A. Rocca, and M. Filippi. (2012) The New England Journal of Medicine. 366 (11): 1000-9.

In November 2011, Tisch MS was approved by the International Cellular Medicine Society (ICMS), an Institutional Review Board (IRB), to begin a phase I safety and tolerability trial of Mesenchymal Stem Cell-Derived Neural Progenitors in 20 selected Multiple Sclerosis patients. The Food and Drug Administration (FDA) recently began an audit of ICMS and questioned whether the Tisch MS protocol was exempt from FDA regulation. Pending the final outcome of the FDA audit, all further work on Tisch MS’s stem cell trial is suspended.

The Tisch MS stem cell research team regrets to announce that the two major grant applications by which we had hoped to fund our proposed clinical trial of stem cell therapy in Multiple Sclerosis have not been approved. An application to the philanthropic arm of the Hearst Foundations was declined outright, while a similar application to the National MS Society remains unapproved pending several changes in the study protocol. The upshot is that work on the clinical trial will be at the very least delayed until sufficient funds can be obtained.

The Tisch MS Research Center of New Yorkis pleased to announce that it has successfully completed the initial steps towards accreditation to serve as a facility for the processing of human stem cells in clinical trials from the International Cellular Medicine Society. Along with soon-to-be-filed applications for additional certifications, this accreditation is an important step towards actually beginning the administration of neural progenitor stem cells to MS patients.

Fozia Mir, PhD, an Assistant Research Scientist at Tisch MS, presented a lecture on “Lipids in Multiple Sclerosis” Wednesday morning.  Lipids are very biologically active compounds that are highly susceptible to oxidative damage due to the presence of double bonds.  Oxidative stress can cause tissue injury, inflammation, and cell death and has been implicated in the pathogenesis of neurodegenerative diseases, including multiple sclerosis (MS).  The brain has a high lipid content which, combined with its high metabolism, low antioxidant levels, and high intracellular iron l

Donald Lee (Tisch MS) presented the following article in Journal Club.

Article Title: Inhibition of Fatty Acid Metabolism Ameliorates Disease Activity in an Animal Model of Multiple Sclerosis

Reference: L.P. Shriver and M. Manchester. Sci. Rep. 1, 79; DOI:10.1038/srep00079 (2011).

Pages